[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@JournalCancer Avatar @JournalCancer ACS Journal Cancer

ACS Journal Cancer posts on X about education, $fro, the daily, strong the most. They currently have XXXXXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXXXXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence

Social category influence finance

Social topic influence education, $fro, the daily, strong, health

Top accounts mentioned or mentioned by @oncoalert @americancancer @ramalingammd @pateloncology @wileyonchem @mskcancercenter @fredhutch @oreganruth @acsnews @nlcrtnews @winshipatemory @mdandersonnews @jennifergrandis @jacquicallander @drhkantarjian @walterstadler5 @thenci @usfda @wileyhealth @kalinskykevin

Top assets mentioned Frontline Ltd. (FRO)

Top Social Posts

Top posts by engagements in the last XX hours

"This preliminary study suggests that envafolimab is a promising effective and safe neoadjuvant option for locally advanced mismatch repair-deficient #ColorectalCancer; confirmation in larger cohorts is awaited. @OncoAlert #CRCSM"
X Link 2025-12-08T15:57Z 31K followers, XXX engagements

"#ASH25 is off and running Editorial Advisory Board member @NitinJainMD soon presents a Phase X trial as part of the Oral Abstract Session on chronic lymphocytic leukemia relapse & Richter transformation. You may find this review of interest: @OncoAlert"
X Link 2025-12-06T14:15Z 31K followers, XXX engagements

"Starting soon at #ASH25 Editorial Advisory Board member @RyanCassaday joins the Education Program panel Frontline Incorporation of Immune Targeting Agents in B-ALL - Triumphs and Challenges See his work on CNS relapse risk in adult ALL: @OncoAlert"
X Link 2025-12-06T18:45Z 31K followers, 1526 engagements

"Next at #ASH25 🧪 Editorial Advisory Board member Dr. Elias Jabbour presents Camelot-2 a Phase X study of a menin-inhibitor regimen for newly diagnosed AML with KMT2A-r or NPM1 mutations. Consider revisiting our #AML Top Advances of the Year: @OncoAlert"
X Link 2025-12-07T22:50Z 31K followers, 1032 engagements

"Could altering the daily timing of immunotherapy improve survival in people with cancer New study finds that earlier administration may be best: @OncoAlert #LCSM"
X Link 2025-12-08T13:57Z 31K followers, 1157 engagements

"With #ASH25 coming to a close its a great moment to think about your next submission. Dr. Courtney DiNardo shares why Cancer is a strong choice for impactful oncology research. Learn more: @OncoAlert @RamalingamMD"
X Link 2025-12-08T17:32Z 31K followers, XXX engagements

"At #ASH25 Editorial Advisory Board member @MDmasarova will share new findings on CK0804 Tregs in myelofibrosis in the upcoming Poster Session on Myeloproliferative Syndromes. Explore her recent work in this space: @OncoAlert"
X Link 2025-12-08T22:45Z 31K followers, XXX engagements

"Just in time for #SABCS25 Metformin with neoadjuvant chemotherapy in localized triple-negative and Her2neu-positive breast cancer: A prospective phase X open-label randomized controlled trial (McBETH) @OncoAlert #ClinicalTrials #BCSM"
X Link 2025-12-09T17:51Z 31K followers, XXX engagements

"At #SABCS25 Editorial Advisory Board member Dr. @KalinskyKevin joins the Clinical Case Discussion panel to weigh in on challenging real-world cases. Hear from him below & access his recent CANCER article on key advances in breast cancer care: @OncoAlert"
X Link 2025-12-10T17:40Z 31K followers, XXX engagements

"Revisit the @AmericanCancer special report on lobular breast cancer statistics during #SABCS25. 🩺11% of US breast cancers are invasive lobular carcinoma 📈 Incidence rising faster than other BCs 📊33600 diagnoses expected in 2025 @OncoAlert"
X Link 2025-12-10T19:09Z 31K followers, XXX engagements

"Coming up at today's #SABCS25 Poster Session CANCER Section Editor Dr. Ruth O'Regan presents data using the Breast Cancer Index to identify premenopausal patients at minimal recurrence risk. Read her recent review on treatment advances: @OncoAlert"
X Link 2025-12-11T17:45Z 31K followers, XXX engagements

"After X additional years of follow-up ripretinib showed a trend toward clinically meaningful OS benefit vs sunitinib in the exon 11-mutated intention-to-treat population. Access the free-to-read analysis: @OncoAlert @WileyHealth #GICancer"
X Link 2025-12-11T20:11Z 31K followers, XXX engagements

"New phase X randomized trial published just in time for #SABCS25 🎯 The SONIA trial: Cognitive function during endocrine treatment with or without cyclin-dependent kinase 4/6 inhibitors for advanced #BreastCancer @OncoAlert @NKI_nl #BCSM"
X Link 2025-12-11T22:25Z 31K followers, XXX engagements

"Results suggest this study establishes natural killer cells as pivotal mediators of sex differences in urothelial carcinoma. #uroonc @OncoAlert"
X Link 2025-12-12T04:55Z 31K followers, XXX engagements

"Physical activity may improve lower-extremity physical performance compared to health education in older adult long-time cancer survivors according to a new multicenter randomized trial led by Dr. Justin C. Brown of @AdventHealth. @OncoAlert"
X Link 2025-12-12T13:59Z 31K followers, XXX engagements

"This real-world study establishes that patients with advanced GISTs treated with ripretinib trough concentrations above XXX ng/mL experience significantly prolonged survival. #FreeAccess supplement article: @OncoAlert @WileyHealth #GICancer"
X Link 2025-12-12T14:32Z 31K followers, XXX engagements

"The current findings suggest that nonhematologic AIDs are prevalent in patients with chronic lymphocytic leukemia and these patients have a better prognosis than patients who have autoimmune cytopenia. @OncoAlert @miguel_argdtom @hematosantpau #leusm"
X Link 2025-12-12T16:19Z 31K followers, XXX engagements

"Look for Editorial Advisory Board member Dr. @KalinskyKevin in the #SABCS25 poster hall sharing new metastatic breast cancer research. Explore additional recent findings in this 2025 CANCER study on HER2-positive breast cancer: @OncoAlert"
X Link 2025-12-12T18:15Z 31K followers, XXX engagements

"New study investigates the prevalence of hypothyroidism and thyroid peroxidase antibodies in a large cohort of Dutch #ChildhoodCancer survivors and examines associations with different treatment modalities: @OncoAlert @prinsesmaximac"
X Link 2025-12-12T19:43Z 31K followers, XXX engagements

"The addition of pembrolizumab to neoadjuvant chemoradiation followed by surgical resection was overall well-tolerated and resulted in numerically higher rates of pathologic complete response compared to historical controls. @OncoAlert"
X Link 2025-12-12T20:32Z 31K followers, XXX engagements